An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture by Cornelissen, J.J. (Jan) et al.
 976
 
Cornelissen et al.
 
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/98/09/0976/08 $2.00
Volume 102, Number 5, September 1998, 976–983
http://www.jci.org
 
An In Vitro Model for Cytogenetic Conversion in CML
 
Interferon-
 
a
 
 Preferentially Inhibits the Outgrowth of Malignant Stem Cells Preserved in Long-Term Culture
 
Jan J. Cornelissen,* Rob E. Ploemacher,
 
‡
 
 Bert W. Wognum,
 
‡
 
 Astrid Borsboom,
 
‡
 
 Hanneke C. Kluin-Nelemans,
 
§
 
 
 
Anne Hagemeijer,
 
i
 
 and Bob Löwenberg*
 
‡
 
*
 
Department of Hematology, Daniel den Hoed Cancer Center, Rotterdam, 3075 EA, The Netherlands; 
 
‡
 
Institute of Hematology, Erasmus 
University Rotterdam, Rotterdam, 3015 GE, The Netherlands; 
 
§
 
Department of Hematology, Leiden University Medical Center, Leiden, 
2333 ZA, The Netherlands; and 
 
i
 
Center for Human Genetics, University of Leuven, Leuven, 3000, Belgium
 
Abstract
 
IFN-
 
a
 
 has been shown to prolong survival in chronic mye-
loid leukemia patients, but its mechanism of action is still
not understood. The human cobblestone area–forming cell
(CAFC) assay allows for the measurement of the concentra-
tion of normal as well as malignant stem cells, while their
progeny can be measured in parallel long-term culture
(LTC) in flasks. Using CAFC and LTC assays, we have ex-
amined direct effects of IFN-
 
a
 
 (500; 5,000 IU/ml) on the
maintenance and outgrowth of CD34-enriched normal and
malignant stem cells, obtained from six patients with an es-
tablished major cytogenetic response to IFN-
 
a
 
 and from
four nonresponding patients. CAFC concentrations were
not affected by IFN-
 
a
 
. In contrast, IFN-
 
a
 
 strongly inhibited
the clonogenic output in flask LTC. Nucleated cells (NC)
produced in LTC were evaluated by fluorescent in situ hy-
bridization (FISH) for the presence of the Philadelphia (Ph)
 
translocation. After 8 wk of LTC, the percentage of Ph
 
1
 
NCs produced was significantly more inhibited by IFN-
 
a
 
 in
responding patients than in nonresponders. Control LTC
without IFN-
 
a
 
 showed no significant differences of Ph
 
1
 
 NC
production between responders and nonresponders. These
findings provide the first in vitro model for cytogenetic con-
version and suggest that direct antiproliferative effects of
IFN-
 
a
 
 account for the cytogenetic response observed clini-
cally. (
 
J. Clin. Invest.
 
 1998. 102:976–983.) Key words: in-
terferon-
 
a
 
 
 
•
 
 long-term culture 
 
•
 
 cobblestone area–forming
cell assay 
 
•
 
 chronic myeloid leukemia 
 
•
 
 cytogenetic response
 
Introduction
 
Chronic myeloid leukemia (CML)
 
1
 
 is a malignant clonal disor-
der of hematopoietic stem cells (1). The neoplastic cells are
characterized by a unique gene rearrangement as a result of a
reciprocal translocation between the long arm of chromosome
9 and chromosome 22, known as Philadelphia chromosome
(Ph) (2). The gene rearrangement results in the creation of a
 
bcr/abl
 
 fusion gene, which encodes for a chimeric protein
(p210) with tyrosine kinase activity (3). Characteristically,
CML has a biphasic course, evolving from chronic phase (CP)
with a median duration of 3–4 yr to an accelerated phase and
blast crisis, which is usually fatal within 3–6 mo. Preferably, pa-
tients are treated in CP in order to postpone or offset blastic
transformation.
Allogeneic bone marrow (BM) transplantation is the only
curative treatment available, but is only applicable in a minor-
ity of patients (15–20%) for whom an HLA identical (sibling)
donor can be found and who are under the age of 50–55 yr (4).
Alternative treatment strategies for patients, who do not have
the option of allogeneic BM transplantation, include IFN-
 
a
 
alone or in combination with chemotherapeutic agents such as
hydroxyurea and cytarabine. Treatment with IFN-
 
a
 
 may pro-
long the overall median survival. Several randomized as well
as nonrandomized studies have shown that survival of patients
treated with IFN-
 
a
 
 may be significantly longer than that of pa-
tients receiving hydroxyurea or busulfan (5–9). However, the
beneficial effect of IFN-
 
a
 
 appears to be restricted to a sub-
group of patients (10–15%) who achieve a partial or complete
cytogenetic response after IFN-
 
a
 
 treatment. The actuarial sur-
 
vival at 5 yr for these patients is 
 
z
 
 90%, while survival for pa-
tients without a cytogenetic response is in the order of 45–50%
at 5 yr, which is probably not different from that observed af-
ter hydroxyurea alone.
Several investigators have addressed the question as to
how IFN-
 
a
 
 may exert its beneficial effects. It has been sug-
gested that IFN-
 
a
 
 may restore defective adhesion of CML pro-
genitors to BM stroma, thereby allowing normal growth inhib-
itory signals to restore physiological regulation of stem cell
growth (10–12). Alternative explanations include a direct anti-
proliferative effect of IFN-
 
a
 
 on CML progenitors or immuno-
logical control of malignant cell growth (13–16). However, the
precise biological basis of the therapeutic effect of IFN-
 
a
 
,
which is predominantly observed in patients with a cytogenetic
response, is still not resolved. It is not known by which biologi-
cal mechanism most CML patients are resistant to IFN-
 
a
 
.
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 BFU-E, burst-forming units eryth-
roid; BM, bone marrow; CA, cobblestone area; CAFC, cobblestone
area–forming cells; CFU-GM, colony-forming units granulocyte mac-
rophage; CML, chronic myeloid leukemia; CP, chronic phase; FISH,
fluorescent in situ hybridization; G-CSF, granulocyte colony-stimu-
lating factor; IC, initiating cells; LTC, long-term culture; NC, nucle-
ated cells; PB, peripheral blood; Ph, Philadelphia.
 
 Antiproliferative Effect of Interferon-
 
a
 
 in Chronic Myeloid Leukemia
 
977
 
Long-term cultures (LTCs) of normal and malignant he-
matopoietic cells have been used to study the relationship be-
tween primitive and committed hematopoietic progenitor cells
and the marrow microenvironment (17). Such studies may po-
tentially help to clarify the biological basis of the therapeutic
effect of IFN-
 
a
 
. We have reported previously on the use of the
murine FBMD-1 stromal cell line to establish a limiting dilu-
tion type long-term stroma-supported culture (LTC) assay that
allows frequency analysis of murine (18, 19), rhesus monkey
(20), and human hematopoietic stem cells (21). In this LTC,
stem cells form phase-dark stroma-associated clones of imma-
ture hemopoietic cells (cobblestone areas, CA) (22). Early ap-
pearing, transient CAs represent spleen colony-forming stem
cells (CFU-S day 12), whereas cells giving rise to late appear-
ing CAs are related to primitive stem cells with long-term re-
populating ability (23). Furthermore, we have shown recently
that the FBMD-1 stromal cell line allows long-term growth of
leukemic stem cells (24, 25). Both leukemic and normal stem
cells obtained from individual CML patients were maintained
efficiently throughout LTC (25). Such LTC provides a model
to evaluate differential effects of cytokines or drugs on normal
and malignant stem cells in CML. In this study we have investi-
gated the inhibitory effects of IFN-
 
a
 
 on the maintenance and
outgrowth of normal and malignant stem cells obtained from
CML patients with a well-documented clinical response to
IFN-
 
a
 
.
 
Methods
 
Patients.
 
BM samples and peripheral blood (PB) samples used for
this study were obtained after informed consent from CML patients
in first CP. Response criteria were as follows. Complete hematologi-
cal responses were: normalization of peripheral white blood cell
counts to levels 
 
,
 
 10,000/
 
m
 
l and normal differentials with no imma-
ture forms (blasts, promyelocytes, myelocytes, or metamyelocytes);
normalization of platelet counts to 
 
,
 
 450,000/
 
m
 
l; disappearance of all
clinical symptoms and signs of disease including palpable spleno-
megaly. Cytogenetic responses were: absent: Ph chromosome persists
in all analyzable metaphases; minimal: Ph chromosome in 
 
.
 
 35% of
metaphases; partial: Ph chromosome in 
 
,
 
 35% of metaphases; com-
plete: total elimination of Ph chromosome cells; major: either com-
plete or partial (
 
$
 
 65% Ph
 
2
 
 cells).
 
Enrichment of CD34
 
1
 
 progenitor cells.
 
Cryopreserved samples
were thawed at 37
 
8
 
C and slowly diluted with Iscove’s medium con-
taining 10% FBS and 3 U/ml of DNase I. Cells were pelleted and re-
suspended for antigen staining in PBS containing 1% FBS (Hyclone,
Logan, UT). Fresh samples were diluted 1:1 with Hanks’ balanced
salt solution (GIBCO BRL, Gaithersburg, MD), and mononuclear
cells were obtained by layering the cells over Ficoll (Lymphoprep;
Nygaard, Oslo, Norway). A CD34
 
1
 
 cell preenriched fraction was pre-
pared by immunomagnetic bead selection by the anti-CD34 mAb 561
coated to immunomagnetic latex beads (Dynal, Oslo, Norway), fol-
lowed by quantitative elution with anti-Fab antiserum (Detacha-
bead). Alternatively, CD34
 
1
 
 cells were purified using avidin-biotin
immunoadsorption columns (CellPro Inc., Bothell, WA) as described
previously (26).
 
Immunofluorescence analysis.
 
CD34 staining was performed by
incubating 10
 
6
 
 nucleated cells (NCs) after erythrocyte lysis for 30 min
with anti-CD34-FITC (HPCA-2 mAb; Becton Dickinson, San Jose,
CA). Incubations were performed in Hanks’ balanced salt solution
containing 2% (wt/vol) FCS and 0.05% (vol/vol) sodium azide. After
incubation the cells were washed and resuspended in Hanks’ bal-
anced salt solution at a concentration of 2 
 
3
 
 10
 
6
 
 cells/ml. Analytical
two-color experiments were performed using a FACScan
 
®
 
 flow cy-
tometer (Becton Dickinson). Spillover of FITC fluorescence in the
RPE detector was electronically compensated using appropriately
stained control cells. List mode data for 10,000–50,000 cells were col-
lected either ungated or in an electronic gate for cells with intermedi-
ate-to-high forward light scatter and low-to-intermediate right angle
light scatter to exclude dead cells and mature granulocytes from the
analysis. Flow cytometric data were analyzed using Lysys II software
(Becton Dickinson).
 
Hematopoietic growth factors.
 
For the in vitro studies the follow-
ing purified recombinant human growth factors were kindly pro-
vided: granulocyte colony-stimulating factor (G-CSF; Amgen, Thou-
sand Oaks, CA), granulocyte-macrophage colony-stimulating factor
(GM-CSF; Genetics Institute, Cambridge, MA), and stem cell factor
(Immunex, Seattle, WA). Purified recombinant human erythropoi-
etin was purchased from Boehringer Mannheim (Mannheim, Ger-
many). IFN-
 
a
 
-2a was obtained from Roche (Mijdrecht, The Nether-
lands).
 
Stromal feeders.
 
The FBMD-1 stromal cell line was used as de-
scribed before (18). In brief, stromal feeders were prepared by seed-
ing 10
 
5
 
 FBMD-1 cells from log-phase cultures into 25-cm
 
2
 
 culture
flasks (Costar Corp., Cambridge, MA) or 10
 
3
 
 cells per well into flat-
bottomed 96-well plates (Falcon, Lincoln Park, NJ). Culture plastics
destined for establishment of FBMD-1 stromal feeders were incu-
bated overnight at 4
 
8
 
C with 0.2% gelatin (Sigma Chemical Co., St.
Louis, MO) in demineralized water to improve adherence of the stro-
mal layer. The FBMD-1 cells were cultured in 
 
a
 
-modified DME
(GIBCO BRL) supplemented with Hepes (3.5 mM; Sigma), glu-
tamine (2 mM; Sigma), sodium-selenite (10
 
2
 
7
 
 M), 
 
b
 
-mercaptoeth-
anol (10
 
2
 
4
 
 M), 10% FCS, 5% horse serum (GIBCO BRL), and hy-
drocortisone 21-hemisuccinate (10
 
2
 
5
 
 M; Sigma). After 7–10 d of
culture at 33
 
8
 
C and 10% CO
 
2
 
, the stromal layers had reached conflu-
ence and were overlaid with CML progenitors within the subsequent
2 wk.
 
LTCs in flasks.
 
Confluent stromal layers of FBMD-1 cells in 25-
cm
 
2
 
 flasks were overlaid with 15–30 
 
3
 
 10
 
3
 
 CD34
 
1
 
 preenriched NCs.
The cells were cultured in 
 
a
 
-modified DME supplemented with
Hepes (3.5 mM), glutamine (2 mM), sodium-selenite (10
 
2
 
7
 
 M), 
 
b
 
-mer-
captoethanol (10
 
2
 
4
 
 M), 20% horse serum, and hydrocortisone 21-
hemisuccinate (10
 
2
 
6
 
 M). IL-3 (12 ng/ml) and G-CSF (20 ng/ml) were
added weekly to the culture. Flask cultures were set up in duplicate
and maintained at 33
 
8
 
C and 10% CO
 
2
 
 for 8 wk with weekly half-
medium changes and removal of half of the nonadherent cells. The
number of NC produced as well as the clonogenic cell output of indi-
vidual flask cultures was determined on weeks 2, 4, 6, and 8. A single
cell suspension was taken up in medium and several concentrations of
the cell suspension were plated in a clonogenic cell assay.
 
Clonogenic cell assays.
 
Quantification of the number of colony-
forming units granulocyte macrophage (CFU-GM) and burst-form-
ing units erythroid (BFU-E) was performed using a semisolid (1%
methylcellulose; Methocel, Stade, Germany) culture medium (Is-
cove’s modified Dulbecco’s medium; GIBCO BRL) at 37
 
8
 
C and 5%
CO
 
2
 
. The cultures contained 10% FCS, 0.75% BSA (A9418; Sigma)
supplemented with human transferrin (0.6 mg/ml; Behringwerke,
Marburg, Germany), lecithin (20 
 
m
 
g/ml; Merck, Darmstadt, Ger-
many), sodium-selenite (0.2 ng/ml; Merck), 
 
b
 
-mercaptoethanol (5 
 
3
 
10
 
2
 
5
 
 M; Merck), erythropoietin (1 U/ml), IL-3 (15 ng/ml), G-CSF (50
ng/ml), GM-CSF (5 ng/ml), and stem cell factor (50 ng/ml) all at final
concentrations. CFU-GM and BFU-E were counted on day 14 of cul-
ture in the same dish. Their added number (CFU-C) is presented as
clonogenic output of LTC.
 
Cobblestone area–forming cell (CAFC) assay.
 
Confluent stromal
layers of FBMD-1 cells in flat-bottomed 96-well plates were overlaid
with NCs in a limiting dilution setup. Input values ranged between 1
and 3,000 NCs per well for purified CD34
 
1
 
 cells. 12 dilutions twofold
apart were used for each sample with 15 replicate wells per dilution.
The cells were cultured in the same medium and under the same con-
ditions as the LTCs in flasks. To diminish the excessive nonadherent
cell production and consequently increase the visibility of the CAs, a
hydrocortisone 21-hemisuccinate concentration of 10
 
2
 
5
 
 M instead of
 978
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10
 
2
 
6
 
 M was used in the CAFC culture medium. The percentage of
wells with at least one phase-dark hematopoietic clone of at least five
cells (i.e., CA) beneath the stromal layer was determined weekly for 6
wk and CAFC frequencies were calculated using Poisson statistics as
described previously (18).
 
Slide preparation for fluorescent in situ hybridization (FISH).
 
Cells were pelleted in 15 ml screw-capped tubes using a table-top cen-
trifuge and washed once with RPMI containing 10 U/ml of heparin.
After a hypotonic shock with 0.075 M KCl for 5 min, cells were fixed
with methanol/acetic acid (3:1) for 15 min. For slide preparation, cells
were applied to clean glass slides. Slides were stored at 
 
2
 
80
 
8
 
C un-
til use.
 
FISH.
 
In double-color FISH, a mixture of 
 
bcr
 
 and 
 
abl
 
 probes was
used, that were labeled by standard nick translation using either bi-
otin-16-dUTP or digoxigenin-11-dUTP (both from Boehringer Mann-
heim). After heat denaturation, 25–50 ng of probe was preannealed
with 10 
 
m
 
g of Cot-1 DNA for 1–3 h at 37
 
8
 
C. The hybridization mix-
ture contained the probes and Cot-1 DNA in 50% formamide, 10%
dextran-sulfate in 2
 
3
 
 SSCP. All details concerning pretreatment of
slides, hybridization, washing, and immunochemical detection were
as reported (27). The probes used were Cos-ABL-18, a 40-kb frag-
ment containing the 3
 
9
 
 coding region of the human 
 
abl
 
 gene, and Cos-
 
bcr
 
-51, containing a 35.5-kb fragment representing most of the first
exon and part of the first intron of 
 
bcr
 
. The slides were analyzed using
a fluorescent microscope equipped with a triple band pass filter for si-
multaneous excitation of FITC, Texas red, and DAPI. All analyses
were performed using cells with good nuclear morphology and com-
plete, nonoverlapping nuclei. For each hybridization experiment, at
least 100 nuclei were scored (technicians were unaware of the clinical
response of the patients). A cell was scored Ph
 
2 
 
if two distinct red and
two distinct green signals were visible within a nucleus. A cell was
scored Ph
 
1
 
 if it contained one distinct red signal, one distinct green
signal, and one distinct yellow signal representing the coincidence of
a red and green signal. In addition, a cell was scored Ph
 
1
 
 if it con-
tained two distinct red signals and two distinct green signals with one
red signal and one green signal in close juxtaposition. All other cells
that contained fewer signals were not scored as Ph
 
1
 
 or Ph
 
2
 
, but were
used to calculate the hybridization frequency, which ranged from 80
to 90% for this study, implying that two 
 
abl
 
 and two 
 
bcr
 
 signals were
visible in at least 80% of all cells. Cytospin slides prepared from
thawed CD34
 
1
 
 selected progenitor cells obtained (after informed
consent) from a patient with established accelerated CML were used
as positive control slides. Cytogenetic evaluation of these CD34
 
1
 
 pro-
genitor cells yielded 100% Ph
 
1
 
 metaphases (30/30) without additional
cytogenetic abnormalities. Evaluation by FISH yielded positivity for
 
bcr/abl
 
 of 97
 
6
 
2% (
 
n
 
 
 
5 
 
8). Cytospin slides prepared from thawed
CD34
 
1
 
 selected progenitor cells obtained (after informed consent)
from a patient with breast cancer were used as negative control slides,
yielding a positivity for 
 
bcr/abl
 
 of 2
 
6
 
1% (
 
n 5 7). Experiments were
considered of sufficient quality if the hybridization frequency was
. 80% and positive and negative controls yielded, respectively, a per-
centage of at least 95% (positive control) and , 5% (negative con-
trol).
Data analysis. Data were analyzed using SlideWrite Plus for
DOS Version 6.0 (Advanced Graphics Software, Carlsbad, CA).
Curve fits were performed using a least squares regression fit. Corre-
lation coefficients were calculated using two-tailed t test or Wilcoxon
rank-sum (Mann-Whitney) test in case of unequal variances.
Results
Patients. Patient characteristics are presented in Tables I and
II. Six patients developed a major cytogenetic response af-
ter IFN-a treatment, including three complete responses and
three partial responses. The median time to their best cytoge-
netic response was z 2 yr (range 8–54 mo). All cytogenetic re-
sponses were preceded by a complete hematological response,
which was achieved at a median time of 3 mo after diagnosis
(range 2–6 mo). Four patients failed to show a cytogenetic re-
sponse after treatment with IFN-a for at least 50 mo (range
59–84 mo). However, two out of these four patients achieved a
complete hematological response. BM or PB samples used for
our experiments were the earliest samples available, which
were obtained within 3 mo of diagnosis for six patients and be-
tween 5 and 28 mo from diagnosis for the other four patients.
Effect of IFN-a on CAFC frequency. CD341 selected cells
were assayed for their concentration of CAFC. Enrichment of
CD341 cells resulted in a mean purity of 75% CD341 cells
(range 49–92%). Stromal layers were overlaid with CD341
NCs in a limiting dilution setup either in the presence or ab-
sence of IFN-a. Initially, IFN-a was added to final concentra-
tions of 50 and 500 IU/ml. No inhibitory effect of IFN-a was
observed when CAFC frequencies were assayed weekly dur-
ing a culture period of 9 wk. This is exemplified for patient 6 in
Fig. 1. As no inhibitory effect was observed, a higher dosage of
IFN-a was also evaluated. Therefore, in subsequent experi-
ments, the dosage of IFN-a was increased to a final concentra-
tion of 5,000 IU/ml, which was added every week to the cul-
tures. Cumulative results with progenitor cells from three
responding and three nonresponding patients are presented in
Fig. 2. Cytogenetic responders were patients 1–3 (Table I) and
nonresponders were patients 7–9 (Table II). CAFC concentra-
tions are presented as percentages of concentrations assayed
by parallel control cultures without IFN-a. No significant in-
Table I. Characteristics of IFN-a Responsive Patients
Patient Age (yr)/sex
Clinical status
at diagnosis
Response to IFN-a
Study sampleHematological Cytogenetic
Type
Time from
diagnosis
% of Ph1
metaphases
Time from 
diagnosis
% of Ph1 
metaphases
Time from
diagnosis Source
mo mo mo
1 40/F CP CHR 6 3 25 100 5 BM
2 28/F CP CHR 3 0 54 100 0 BM
3 52/M CP CHR 2 0 47 100 0 BM
4 56/F CP CHR 2 0 14 100 0 PB
5 24/F CP CHR 3 25 29 81 18 BM
6 56/M CP CHR 2 35 8 100 0 PB
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hibitory effect was observed after 8 wk of culture. Neither the
number nor the size of CA (results not shown) was affected by
IFN-a in responding as well as nonresponding patients.
Effects of IFN-a on production of NCs and committed pro-
genitors. CD341 selected progenitor cells were also cultured
in flask LTC. Stromal layers of FBMD-1 cells were overlaid
with CD341 progenitor cells and the number of NCs produced
was determined every other week. In addition, NCs produced
were assayed for CFU-GM and BFU-E recovery after plating
in secondary clonogenic cell cultures. The cumulative produc-
tion of CFU-GM and BFU-E after 8 wk of culture was calcu-
lated. Results are shown in Figs. 3 and 4. Weekly addition of
IFN-a to flask LTC resulted in a significant and dose-depen-
dent inhibition of the production of NC and the production of
CFU-GM and BFU. Production was inhibited in all patients,
including cytogenetically responding as well as nonresponding
patients. After 8 wk of flask LTC, nonadherent cells were re-
moved and assayed as described. Subsequently, adherent cells
were also removed and assayed for CFU-GM and BFU-E re-
covery after plating in secondary clonogenic cultures. Results
are presented in Fig. 5. Adherent cells from flask LTC without
weekly addition of IFN-a produced significantly more CFU-C
than adherent cells from flask cultures to which IFN-a was
added weekly to concentrations of 500 or 5,000 IU/ml. No
differences were apparent between responders and nonre-
sponders.
The total number of nonadherent NC and CFU-C assayed
during 8 wk of LTC represented all cells produced with no re-
gard to the leukemic or normal nature of the cells. To distinc-
tively evaluate the production of normal NC as compared with
Ph1 NC, cells were analyzed by FISH with bcr and abl specific
probes.
Effect of IFN-a on production of Ph1 NCs. FISH analysis
was performed on CD341 progenitor cells before LTC and on
NC produced after 8 wk of LTC to determine the percentages
of bcr/abl positive cells. Percentages for individual patients are
shown in Fig. 6, whereas median values and statistical analysis
are presented in Table III. Both normal and leukemic cells
were detectable before LTC in samples from responding
patients as well as nonresponders. Median percentages of
CD341/Ph1 NC did not differ between the two groups of pa-
tients, although a wider range was observed in progenitor cells
from responding patients (27–95%). In both responders and
nonresponders, the percentage of Ph1 cells did not change sig-
nificantly during 8 wk of LTC in the absence of IFN-a, con-
Table II. Characteristics of IFN-a Refractory Patients
Patient Age (yr)/sex
Clinical status
at diagnosis
Response to IFN-a
Study sampleHematological Cytogenetic
Type
Time from
diagnosis
% of Ph1
metaphases
Time from
diagnosis
% of Ph1
metaphases
Time from
diagnosis Source
mo mo mo
7 62/M CP CHR 3 100 , 59 100 0 BM
8 48/M CP Partial 100 , 63 100 0 BM
9 59/M CP Partial 100 , 60 100 6 BM
10 29/M CP CHR 6 100 , 84 100 28 BM
Figure 1. Weekly CAFC frequencies per 105 CD341 NC, obtained 
from the BM of patient 5, cultured without IFN-a (open circles), or in 
the presence of 50 IU (open boxes), or 500 IU (open diamonds) IFN/
ml at final concentrations.
Figure 2. CAFC week 8 frequencies per 105 CD341 NC expressed as 
mean percentages (6SEM) of parallel control cultures without IFN-a. 
IFN-a was added weekly to final concentrations of 500 or 5,000 U/ml. 
CD341 NC were obtained from BM samples of clinically responding 
patients (n 5 3) and patients (n 5 3) without a cytogenetic response 
to IFN-a.
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firming earlier findings that LTC on the FBMD-1 stromal cell
line equally supports outgrowth of Ph1 and Ph2 progenitors
(25). The percentage of Ph1 NC produced by progenitor cells
from nonresponders did not change over 8 wk of LTC in the
presence of IFN-a. In contrast, the production of Ph1 NC by
progenitors from responding patients declined from 80 to 31%
after 8 wk of LTC in the presence of 5,000 IU/ml IFN-a. The
difference between responders and nonresponders was signifi-
cant (P 5 0.011, Table III). In addition, the percentage of Ph1
NC produced by responders either in the absence or presence
of 5,000 IU/ml IFN-a (80 vs. 31%) was also significant (P 5
0.03). The median percentage of Ph1 NC produced in the
presence of 500 IU/ml IFN-a also declined to 45 and 66%, re-
spectively, for responding and nonresponding patients, but this
difference was of borderline significance (P 5 0.077). Control
LTC that did not include IFN-a showed no statistically sig-
nificant difference (P 5 0.16) between the percentages of Ph1
NC in responding (51%) and nonresponding (57%) patients.
Discussion
Treatment of CML patients with IFN-a may induce hemato-
logic remissions in up to 75% of patients, while a cytogenetic
remission may follow in z 15–20% of patients (5–9, 28). More-
over, IFN-a has been shown to significantly prolong survival in
CP CML. However, the survival benefit is restricted to the
subgroup of patients, who develop a cytogenetic conversion as
indicated by a reappearance of normal BM metaphases. A he-
matological response is usually achieved within 2–3 mo, but a
cytogenetic response develops more slowly and it may take
Figure 3. NCs produced at weeks 2, 4, 6, and 8 in flask LTC ex-
pressed as mean percentages (6SEM) of parallel control LTC with-
out IFN-a. Final concentrations of weekly added IFN-a were 500 and 
5,000 U/ml, respectively. NC production of cytogenetic responders 
(n 5 3) and nonresponders (n 5 3) were compared.
Table III. Effect of IFN on Ph1 Cell Production in LTC
LTC
time point IFN dosage added
Percentage of Ph1 nucleated cells
P value
Responders
(n 5 6)
Nonresponders 
(n 5 4)
Median Range Median Range
wk IU/ml
0 — 80 27–95 73 65–83 0.67
8 0 51 42–64 57 47–84 0.16
8 500 45 37–48 68 47–91 0.077
8 5000 31 10–40 66 52–89 0.011
FISH analysis was performed on CD341 NC before LTC and on NC
produced after 8 wk of LTC either in the presence or absence of IFN-a.
Median percentages of Ph1 and Ph2 NC are presented separately for re-
sponding and nonresponding patients and were compared using the
Wilcoxon rank-sum test.
Figure 4. Nonadherent clonogenic cell production at weeks 2, 4, 6, 
and 8 in flask LTC in the presence of 500 or 5,000 IU/ml IFN-a ex-
pressed as mean percentages (6SEM) of parallel control LTC with-
out IFN-a. Responding patients (n 5 3) and nonresponders (n 5 3) 
were compared.
Figure 5. Clonogenic cell production by adherent cells removed after 
abrogation of flask LTC after 8 wk of culture in the presence or ab-
sence of IFN-a. Results are expressed as percentages of production 
by adherent cells from LTC without addition of IFN-a. No significant 
differences between responders and nonresponders were observed.
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many months before patients have reached their best cytoge-
netic response to IFN-a (Tables I and II) (7–9). The underly-
ing biological mechanism of that favorable and specific effect
of IFN-a is still poorly understood. LTC of normal and malig-
nant hematopoietic progenitor cells in vitro in the presence of
IFN-a may potentially help to settle the biological basis of that
therapeutic effect of IFN-a. In this study we show that IFN-a
does not eradicate normal or malignant CAFCs maintained in
LTC, but inhibits their outgrowth. Furthermore, IFN-a prefer-
entially inhibits the outgrowth of malignant progenitor cells
obtained from patients with a clinical cytogenetic response. In
contrast, no preferential inhibition is exerted by IFN-a on the
outgrowth of malignant progenitor cells from clinical nonre-
sponsive patients. These in vitro findings mimic the clinical
pattern of cytogenetic conversion induced by IFN-a and sug-
gest that inhibition of the outgrowth of CML progenitor cells
might account for the cytogenetic response to IFN-a.
CML is a malignancy of hematopoietic stem cells and their
maintenance in LTC is a prerequisite to study antiproliferative
effects of cytokines such as IFN-a in vitro for a prolonged pe-
riod of time. It has been reported that LTCs supported by hu-
man stromal feeders of CML progenitors are hampered by a
defective maintenance of malignant but not of normal progen-
itors (29, 30). Previously, we showed that both malignant and
normal stem cells can be maintained for 1–2 mo efficiently in
LTC, if supported by the murine cell line FBMD-1 (25). A
stromal cell line of murine origin offers an additional advan-
tage in that murine cells lack the receptor for human IFN-a,
which enabled us to study direct effects of IFN-a on stem cells.
In addition, the relatively long time span of the LTC assay may
allow for measuring effects of IFN-a, which more closely re-
semble the delayed therapeutic effect in vivo. First we ad-
dressed the question of whether IFN-a eliminates primitive
progenitor cells. No such effect was observed as indicated by
unaltered frequencies of CAFC in the presence of IFN-a. We
demonstrated previously a distinct phenotype and distinct
functional characteristics of early and late CAFC in sorted BM
samples (21). Early CAFC are considered to represent more
transiently repopulating stem cells, while week 5–8 CAFC are
related to primitive stem cells with long-term ability to pro-
duce committed progenitors of different lineages. Late (weeks
5–8) CAFC are preferentially confined to the subset of CD341
Rho-123dull, DR2, 5FU-resistant normal human BM progeni-
tor cells. By sharing multiple functional and phenotypic char-
acteristics with LTC initiating cells (LTC-IC), late CAFC and
LTC-IC probably represent a comparable subset of progenitor
cells (23, 31). Recently, we showed that phenotypically defined
subsets of CD341 (subfractionated on the basis of CD382 ex-
pression) CML progenitors showed distinct patterns of early
and late appearing CAFC and did not differ from their normal
counterparts, indicating that late appearing CAFC of CML PB
or BM can be compared with week 5 LTC-IC (25). In the
present study, IFN-a did not affect the frequency of early
(weeks 2 and 3) CAFC nor late appearing (weeks 5–8) CAFC
(Figs. 1 and 2), indicating that these stem cell subsets were not
eliminated by IFN-a in that time period of LTC.
Theoretically, it is possible that malignant CAFC could be
inhibited, whereas Ph2 CAFC could be expanded (or vice
versa). In that situation, the number of CAFC (Ph1 and Ph2)
could remain unchanged, as observed. However, to date, we
have never observed adult stem cell expansion in our CAFC
system and it would be very unlikely that an inhibitory cyto-
kine like IFN-a would exert such an expansion effect.
The second question, of whether IFN-a affects the progeny
produced by CML CAFC, was studied by assaying the genera-
tion of committed progenitors in flask LTC. The production of
NC and CFU-C by normal and malignant CAFC was dose-
dependently inhibited by IFN-a (Figs. 3 and 4). These results
compare well to earlier studies by Galvani et al., who showed
that IFN-a preferably inhibited more committed progenitors of
both normal and malignant origin (32). A preferential inhibi-
tion of late progenitors may be explained by findings of Eaves
et al., showing that more late than early progenitors are in cell
cycle than early progenitors and may therefore be more re-
sponsive to the antiproliferative effects of IFN-a (33).
In this study, IFN-a inhibited the cell production by malig-
nant CAFC from responding patients and nonresponding pa-
tients, but a relative stronger inhibition was observed with
respect to the NC production of malignant CAFC from re-
sponders (Fig. 6 and Table III). These findings may be ex-
plained by a direct inhibitory effect of IFN-a or by indirect in-
hibition mediated by stromal cells after increased adhesion of
CML progenitors to BM stroma. Several studies have shown
that adhesion of CML progenitors to stromal cells is impaired.
IFN-a may restore adhesion to BM stroma (10–12, 34), which
may result in integrin-mediated inhibition of proliferation of
CML progenitors. An effect of IFN-a on CML stem cells act-
ing via increased adhesion to stromal cells is probably not in-
volved in our study. Stroma-associated CFU-C production was
not increased by IFN-a. On the contrary, CFU-C production
by adherent cells removed from flask LTC was similarly inhib-
ited by IFN-a as the production of CFU-C by nonadherent
cells (Fig. 5). These results as well as the unaltered week 8
CAFC frequencies strongly suggest that the inhibition of non-
adherent CFU-C generation by IFN-a did not result from en-
hanced progenitor adhesion. An indirect effect of IFN-a via
stroma cells is also less likely because the stromal cells do not
express receptors for human IFN-a. Nevertheless, inhibitory
Figure 6. Percentages of Ph1 CD341 NC before LTC in the presence 
of 5,000 IU/ml IFN-a as compared with the percentage of Ph1 NC 
produced after 8 wk of LTC by CD341 NC of patients with a clinical 
cytogenetic response (n 5 6) or without a cytogenetic response (n 5 4).
982 Cornelissen et al.
effects mediated by stromal cells could be involved. It is possi-
ble, as indicated by findings by Bhatia et al. (12), that IFN-a
restores normal signaling through b1-integrins by restoring a de-
fective signaling pathway within the malignant cell. Clinically,
clear-cut differences between cytogenetically responding pa-
tients and nonresponders with respect to restoration of integrin
signaling by IFN-a have not been reported yet. Therefore, it re-
mains to be demonstrated whether b1-integrin–mediated
inhibition accounts for the cytogenetic response observed clini-
cally.
Alternatively, our results are more readily explained by a
direct inhibitory effect via the IFN-a signaling pathway, which
may result in cell cycle exit. Several hematopoietic cell lines re-
spond to IFN-a by a cell cycle arrest at the G0/G1 phase, char-
acterized by the accumulation of nondividing cells with 2n
DNA content (35–39). Specific interactions between IFN-a re-
ceptor–generated signaling and the cell cycle phase have been
identified. It has been shown that IFN-a may impose a number
of proliferative restrictions via cell cycle controlling genes such
as inhibition of cyclin-dependent kinases (40), downregulation
of c-myc, and reduction of DNA binding activity of E2F (41).
On the other hand, enhanced tyrosine kinase activity of
p210BCR/ABL may enhance the activity of E2F and thereby ini-
tiate transcription of c-myc (42). However, the opposing ef-
fects of IFN-a and p210BCR/ABL on the cell cycle remain largely
to be investigated. Such studies may give a clue as to how IFN-a
exerts an antiproliferative effect without elimination of CAFC,
as demonstrated in this study. Our in vitro findings compare
well to previous clinical findings by Talpaz et al. (43) and by
Hochhaus et al. (44). Both clinical studies demonstrated that
the persistence of leukemic progenitors during IFN-a induced
cytogenetic remission. It was suggested that IFN-a interferes
with the maturation and expansion of leukemic progenitors.
Our results would suggest that IFN-a may predominantly af-
fect hematopoietic progenitor cells at a stage of development
beyond the initiation of CAs.
In conclusion, this work presents the first in vitro model
mimicking the cytogenetic conversion induced by IFN-a in
CML. It suggests that cytogenetic responses are predomi-
nantly induced by a preferential functional inhibition of the
outgrowth of CML stem cells.
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